查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612194

抗体契约製造市场：按抗体类型、来源、服务和最终用户划分 - 2025-2030 年全球预测

Antibodies Contract Manufacturing Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Source (Mammalian, Microbial), Services, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗体契约製造市场价值为163.4亿美元，预计到2024年将达到180.4亿美元，复合年增长率为10.82%，到2030年将达到335.6亿美元。

在抗体契约製造中，我们将治疗、诊断和研究所必需的抗体的生产委託给专门的第三方组织。慢性疾病的日益普及、个人化医疗的日益重要性以及对新型疗法的需求推动了对抗体製造的需求，这些因素共同推动了对可扩展且可靠的製造能力的需求。应用范围涵盖製药、生物技术、学术研究和诊断，最终用途主要用于治疗性单株抗体、多株多株抗体、生物相似药和抗体片段。关键的成长要素包括生物技术的进步、生技药品的兴起以及全球医疗基础设施的扩张。此外，高通量筛检和改进的表达系统等技术创新正在推动市场扩张。目前的机会存在于新兴国家的开拓市场，这些国家对先进医疗保健解决方案的需求不断增加，以及双特异性抗体和抗体药物复合体等利基市场。为了抓住这些机会，公司必须注重策略伙伴关係和产能扩张，以满足对不同类型抗体不断增长的需求。然而，市场面临严格的法律规范、复杂的製造流程、高製造成本和智慧财产权问题等挑战。透过有效的品管系统和简化的生产技术解决这些障碍可以降低风险。改进的表现系统（例如 CHO 细胞）、永续製造方法以及透过人工智慧进行的流程优化等创新提供了取得重大进展的潜力。生物相似药抗体和个人化医疗解决方案的探索也提供了重要的成长途径。整体而言，这个市场的特征是技术进步快、竞争动态，要求企业不断创新和适应。透过专注于永续、业务效率和全球企业发展，企业可以在这一繁荣中占据有利地位。

主要市场统计
基准年[2023] 163.4亿美元
预计年份 [2024] 180.4亿美元
预测年份 [2030] 335.6亿美元
复合年增长率（%） 10.82%

市场动态：快速发展的抗体契约製造市场的关键市场洞察

抗体契约製造市场正在因供需的动态相互作用而发生转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 生物製药疗法的开发和商业化的需求
    • 对治疗慢性疾病的先进抗体的需求不断增长
    • 对个人化药物的偏好日益增长
  • 市场限制因素
    • 对生技药品开发和製造的担忧
  • 市场机会
    • 增加生技药品管道并扩大契约製造服务
    • 全球抗体生产研发预算增加
  • 市场挑战
    • 双/多特异性抗体形式的复杂性

波特的五力战略工具驾驭契约製造市场

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗体契约製造市场的外部影响

外部宏观环境因素在塑造抗体契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗体契约製造市场的竞争状况

抗体契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗体契约製造市场供应商绩效评估

FPNV定位矩阵是评估抗体契约製造市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘抗体契约製造市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对抗体契约製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生物製药疗法的开发和商业化的需求
      • 对治疗慢性疾病的先进抗体的需求不断增长
      • 对个人化医疗的兴趣日益浓厚
    • 抑制因素
      • 对生技药品开发和製造的担忧
    • 机会
      • 增加生物製药管道并扩大契约製造服务
      • 增加全球抗体生产的研发预算
    • 任务
      • 双/多特异性抗体形式的复杂性
  • 市场区隔分析
    • 抗体类型：单株抗体因其同质性、特异性和大规模生产能力而受到很高的需求。
    • 最终用户：抗体契约製造越来越多地被生物技术和製药公司采用，以利用他们在抗体生产和精製的专业知识。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 按抗体类型分類的抗体契约製造市场

  • 单株抗体
  • 多株抗体

第七章 抗体契约製造市场：依来源分类

  • 哺乳动物的
  • 微生物

第八章抗体契约製造市场：依服务分类

  • 分析开发和品管
  • 细胞株开发
  • 製程开发

第九章 抗体契约製造市场：依最终用户分类

  • 学术研究机构
  • 生物技术和製药公司

第十章 北美和南美抗体契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太抗体契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲的抗体契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 三星生物製品公司与 LEGOChem Biosciences 建立策略伙伴关係，加速固态肿瘤治疗的 ADC 创新
    • Aragen 在班加罗尔工厂投资 3,000 万美元，加强生物製药生产能力
    • KBI Biopharma 推出 SUREmAb，单株抗体开发与加速製造解决方案
  • 战略分析和建议

公司名单

  • Abeomics
  • Absolute Antibody by LSBio
  • Advanced ChemTech, Inc.
  • AGC Biologics
  • Antibodies, Inc.
  • AstraZeneca
  • Boehringer Ingelheim Biopharmaceuticals GmbH.
  • Bryllan LLC
  • Catalent, Inc.
  • CD BioSciences
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • FUJIFILM Holdings Corporation
  • Fujirebio Inc. by HU Group Holdings, Inc.
  • Hycult Biotechnology（HBT）BV
  • Labcorp Drug Development
  • Lonza Group Ltd.
  • Merck KGaA
  • Molecular Depot LLC
  • Pierre Fabre SA
  • Samsung Biologics
  • Sapphire Bioscience Pty. Ltd.
  • Scantibodies Laboratory, Inc.
  • Synthon International Holding BV
  • The Serum Institute of India
  • WuXi Biologics Co., Ltd.
Product Code: MRR-742BD517AE6B

The Antibodies Contract Manufacturing Market was valued at USD 16.34 billion in 2023, expected to reach USD 18.04 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 33.56 billion by 2030.

Antibodies contract manufacturing involves outsourcing the production of antibodies, crucial for therapeutic, diagnostic, and research purposes, to specialized third-party organizations. The necessity for antibodies manufacturing arises from the increasing prevalence of chronic diseases, the growing importance of personalized medicine, and the demand for novel therapeutics, which together underscore the need for scalable, reliable production capabilities. Applications span across pharmaceuticals, biotechnology, academic research, and diagnostics, with end-use predominantly in therapeutic monoclonal antibodies, polyclonal antibodies, biosimilars, and antibody fragments. Key growth influencers include advancements in biotechnology, the rise of biologics, and the expansion of healthcare infrastructure globally. Moreover, technological innovations, such as high-throughput screening and improved expression systems, propel market expansion. Current opportunities lie in untapped markets in emerging economies where demand for advanced healthcare solutions is rising and in niches like bispecific antibodies and antibody-drug conjugates. To seize these opportunities, businesses should focus on strategic partnerships and capacity expansion to accommodate the growing demand for diverse antibody types. However, the market faces challenges such as stringent regulatory frameworks, complex manufacturing processes, the high cost of production, and intellectual property rights issues. Addressing these barriers with efficient quality control systems and streamlined production technologies can mitigate risks. Innovations such as improvements in expression systems (e.g., CHO cells), sustainable production practices, and AI-driven process optimization offer the potential for substantial advancements. Exploring biosimilar antibodies and personalized medicine solutions also presents significant growth avenues. Overall, this market is characterized by rapid technological advancements and competitive dynamics, challenging companies to constantly innovate and adapt. By focusing on sustainable development, operational efficiency, and expanding global reach, businesses can position themselves advantageously within this thriving industry.

KEY MARKET STATISTICS
Base Year [2023] USD 16.34 billion
Estimated Year [2024] USD 18.04 billion
Forecast Year [2030] USD 33.56 billion
CAGR (%) 10.82%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibodies Contract Manufacturing Market

The Antibodies Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Development and commercialization need for biopharmaceutical therapeutics
    • Surging need for advanced antibodies for the treatment of chronic diseases
    • Rising preference for personalized medicines
  • Market Restraints
    • Concerns regarding development and manufacturing of biologics
  • Market Opportunities
    • Growing number of biologics pipelines and growing contract manufacturing service
    • Increasing the R&D budget for the production of antibodies globally
  • Market Challenges
    • Complexity of bi/multispecific antibody formats

Porter's Five Forces: A Strategic Tool for Navigating the Antibodies Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibodies Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibodies Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibodies Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibodies Contract Manufacturing Market

A detailed market share analysis in the Antibodies Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibodies Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibodies Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibodies Contract Manufacturing Market

A strategic analysis of the Antibodies Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibodies Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abeomics, Absolute Antibody by LSBio, Advanced ChemTech, Inc., AGC Biologics, Antibodies, Inc., AstraZeneca, Boehringer Ingelheim Biopharmaceuticals GmbH., Bryllan LLC, Catalent, Inc., CD BioSciences, Charles River Laboratories International, Inc., Eli Lilly and Company, FUJIFILM Holdings Corporation, Fujirebio Inc. by H.U. Group Holdings, Inc., Hycult Biotechnology (H.B.T.) B.V., Labcorp Drug Development, Lonza Group Ltd., Merck KGaA, Molecular Depot LLC, Pierre Fabre S.A, Samsung Biologics, Sapphire Bioscience Pty. Ltd., Scantibodies Laboratory, Inc., Synthon International Holding B.V., The Serum Institute of India, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibodies Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Antibody Type, market is studied across Monoclonal Antibodies and Polyclonal Antibodies.
  • Based on Source, market is studied across Mammalian and Microbial.
  • Based on Services, market is studied across Analytical Development & Quality Control, Cell Line Development, and Process Development.
  • Based on End-User, market is studied across Academics & Research Institutions and Biotechnology & Pharmaceuticals Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development and commercialization need for biopharmaceutical therapeutics
      • 5.1.1.2. Surging need for advanced antibodies for the treatment of chronic diseases
      • 5.1.1.3. Rising preference for personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns regarding development and manufacturing of biologics
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing number of biologics pipelines and growing contract manufacturing service
      • 5.1.3.2. Increasing the R&D budget for the production of antibodies globally
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of bi/multispecific antibody formats
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Antibody Type: Growing need for monoclonal antibodies due to their uniformity, specificity, and large-scale production capabilities
    • 5.2.2. End-User: Rising adoption of antibodies contract manufacturing among biotechnology & pharmaceutical firms to leverage specialized expertise in antibody production and purification
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibodies Contract Manufacturing Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibodies Contract Manufacturing Market, by Source

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Microbial

8. Antibodies Contract Manufacturing Market, by Services

  • 8.1. Introduction
  • 8.2. Analytical Development & Quality Control
  • 8.3. Cell Line Development
  • 8.4. Process Development

9. Antibodies Contract Manufacturing Market, by End-User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutions
  • 9.3. Biotechnology & Pharmaceuticals Companies

10. Americas Antibodies Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antibodies Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antibodies Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Samsung Biologics and LegoChem Biosciences Forge Strategic Alliance to Accelerate ADC Innovation for Solid Tumor Treatment
    • 13.3.2. Aragen Invests USD 30 Million in Bangalore Facility to Boost Biologics Manufacturing Capabilities
    • 13.3.3. KBI Biopharma Unveils SUREmAb, Monoclonal Antibody Development with Accelerated Manufacturing Solutions
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeomics
  • 2. Absolute Antibody by LSBio
  • 3. Advanced ChemTech, Inc.
  • 4. AGC Biologics
  • 5. Antibodies, Inc.
  • 6. AstraZeneca
  • 7. Boehringer Ingelheim Biopharmaceuticals GmbH.
  • 8. Bryllan LLC
  • 9. Catalent, Inc.
  • 10. CD BioSciences
  • 11. Charles River Laboratories International, Inc.
  • 12. Eli Lilly and Company
  • 13. FUJIFILM Holdings Corporation
  • 14. Fujirebio Inc. by H.U. Group Holdings, Inc.
  • 15. Hycult Biotechnology (H.B.T.) B.V.
  • 16. Labcorp Drug Development
  • 17. Lonza Group Ltd.
  • 18. Merck KGaA
  • 19. Molecular Depot LLC
  • 20. Pierre Fabre S.A
  • 21. Samsung Biologics
  • 22. Sapphire Bioscience Pty. Ltd.
  • 23. Scantibodies Laboratory, Inc.
  • 24. Synthon International Holding B.V.
  • 25. The Serum Institute of India
  • 26. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODIES CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICALS COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023